Smitherman Andrew B, Wilkins Tania M, Blatt Julie, Dusetzina Stacie B
*The Division of Pediatric Hematology & Oncology †UNC Lineberger Comprehensive Cancer Center ‡UNC Eshelman School of Pharmacy §The UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC.
J Pediatr Hematol Oncol. 2016 Aug;38(6):423-8. doi: 10.1097/MPH.0000000000000548.
Long-term survivors of childhood cancers are at increased risk for hospitalization. To test the hypothesis that many treatment-related morbidities are identifiable in the early posttherapy period, we determined the rates and causes for hospitalization among survivors of leukemia and lymphoma during the first 3 years posttherapy. Using a health plan claims database, we identified patients aged 0 to 21 years old treated for leukemia or lymphoma from 2000 to 2010. Survivors were matched 10:1 with similar children without a history of cancer. Hospitalization rates over 3 years were compared using Cox proportional hazards regression and risks of cause-specific hospitalization were compared using log-binomial models. Nineteen percent of childhood leukemia and lymphoma survivors were hospitalized in the first 3 years off therapy. Leukemia survivors (N=529) experienced over 6 times (hazard ratio=6.3; 95% confidence interval [CI], 4.9-8.0) and lymphoma survivors (N=454) over 3 times the hospitalization rate of controls (hazard ratio=3.2; 95% CI, 2.5-4.2). Compared with children without a cancer history, survivors were at increased risk for hospitalization due to infectious causes (leukemia: relative risk [RR], 60.0; 95% CI, 23.4-154.0; lymphoma: RR, 10.0; 95% CI, 4.4-22.9). In addition, lymphoma survivors were at increased risk for cardiovascular-related (RR, 15.0; 95% CI, 5.4-42.0) and pulmonary-related (RR, 8.1; 95% CI, 3.9-16.8) hospitalizations. These findings highlight the morbidity experienced by survivors and suggest that treatment-associated complications may be emerging soon after therapy completion.
儿童癌症的长期幸存者住院风险增加。为了验证许多与治疗相关的疾病在治疗后早期即可识别的假设,我们确定了白血病和淋巴瘤幸存者在治疗后前3年的住院率及原因。利用一个健康计划理赔数据库,我们识别出了2000年至2010年间接受白血病或淋巴瘤治疗的0至21岁患者。将幸存者与10名无癌症病史的类似儿童进行1:1匹配。使用Cox比例风险回归比较3年期间的住院率,并使用对数二项式模型比较特定病因住院的风险。19%的儿童白血病和淋巴瘤幸存者在停止治疗后的前3年住院。白血病幸存者(N = 529)的住院率是对照组的6倍多(风险比 = 6.3;95%置信区间[CI],4.9 - 8.0),淋巴瘤幸存者(N = 454)的住院率是对照组的3倍多(风险比 = 3.2;95% CI,2.5 - 4.2)。与无癌症病史的儿童相比,幸存者因感染性病因住院的风险增加(白血病:相对风险[RR],60.0;95% CI,23.4 - 154.0;淋巴瘤:RR,10.0;95% CI,4.4 - 22.9)。此外,淋巴瘤幸存者因心血管相关(RR,15.0;95% CI,5.4 - 42.0)和肺部相关(RR,8.1;95% CI,3.9 - 16.8)住院的风险增加。这些发现凸显了幸存者所经历的疾病,并表明治疗相关并发症可能在治疗完成后不久就会出现。